 |
 Video: What is a Stock Split?
|
|
|
| Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications. According to our VNDA split history records, Vanda Pharmaceuticals has had 0 splits. | |
|
Vanda Pharmaceuticals (VNDA) has 0 splits in our VNDA split history database.
Looking at the VNDA split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Vanda Pharmaceuticals shares, starting with a $10,000 purchase of VNDA, presented on a split-history-adjusted basis factoring in the complete VNDA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/25/2014 |
|
| End date: |
04/23/2024 |
|
| Start price/share: |
$13.04 |
|
| End price/share: |
$4.63 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-64.49% |
|
| Average Annual Total Return: |
-9.83% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$3,552.20 |
|
| Years: |
10.00 |
|
|
|
|
|
